MALIN ADAMS: Open Payments
NPI 1437824224 · FORT WAYNE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$827 in 36 payments from 13 companies in 2025. Trend: 2023 $19 · 2024 $119 · 2025 $827
Food & beverage: $827
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $138 |
| ABBVIE INC. | 6 | $118 |
| Eisai Inc. | 1 | $97 |
| QOL Medical, LLC | 5 | $85 |
| Ipsen Biopharmaceuticals, Inc | 4 | $71 |
| Madrigal Pharmaceuticals | 3 | $69 |
| Novo Nordisk Inc | 2 | $57 |
| Janssen Biotech, Inc. | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $37 |
Products named: EOHILIA, Leqembi, Sucraid, RINVOQ, IQIRVO, REZDIFFRA, Wegovy, TREMFYA.
Industry payments across IN — which companies pay providers there.
